May 14, 2024
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
arrow icon
arrow icon

MEACOR, an IM Capital portfolio company under USAID-funded MENA II, announced the successful closing of its $15 million Series A funding round. This substantial investment supports MEACOR’s mission to offer a novel transcatheter approach for the treatment of mitral and tricuspid valve regurgitation.

This funding round highlights the potential of MEACOR’s technology to enhance valvular heart repair. “With this capital, we can strategically grow our team to rapidly achieve critical milestones while maintaining our lean and efficient R&D and clinical operations,” said Toufic Azar, CEO and Co-founder of MEACOR.

The company is thrilled to welcome Dr. Azeem Latib and Dr. Susheel Kodali, renowned key opinion leaders in interventional cardiology, as senior clinical advisors. Additionally, Rick Geoffrion, a serial entrepreneur in interventional cardiology devices, joins the team as a senior business advisor.

MEACOR is a privately held medical device company dedicated to developing innovative solutions for minimally invasive heart valve repair using groundbreaking transcatheter cryoadhesion technology to significantly impact the lives of patients worldwide, including shorter recovery times, reduced complication risks, and lower overall costs.